Sonoma Pharmaceuticals, Inc.
SNOA
$1.10
-$0.03-2.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 36.68% | 26.83% | 25.02% | 17.43% | 12.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.68% | 26.83% | 25.02% | 17.43% | 12.19% |
| Cost of Revenue | 37.30% | 22.53% | 26.73% | 18.30% | 10.43% |
| Gross Profit | 35.68% | 34.49% | 22.31% | 16.01% | 15.17% |
| SG&A Expenses | 3.31% | -3.75% | -0.19% | -1.98% | -2.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.18% | 11.13% | 12.53% | 6.99% | 3.22% |
| Operating Income | 33.67% | 38.02% | 27.06% | 21.62% | 21.08% |
| Income Before Tax | -17.61% | 7.70% | 8.61% | 31.13% | 42.22% |
| Income Tax Expenses | -144.36% | -900.00% | 205.36% | 2,470.59% | 380.61% |
| Earnings from Continuing Operations | 8.16% | 10.09% | 5.62% | 22.04% | 28.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.16% | 10.09% | 5.62% | 22.04% | 28.50% |
| EBIT | 33.67% | 38.02% | 27.06% | 21.62% | 21.08% |
| EBITDA | 34.99% | 39.07% | 27.53% | 21.66% | 21.06% |
| EPS Basic | 37.87% | 48.46% | 55.28% | 75.57% | 78.94% |
| Normalized Basic EPS | 20.71% | 48.19% | 57.57% | 77.65% | 82.09% |
| EPS Diluted | 37.87% | 48.46% | 55.28% | 75.57% | 78.94% |
| Normalized Diluted EPS | 20.71% | 48.19% | 57.57% | 77.65% | 82.09% |
| Average Basic Shares Outstanding | 35.73% | 60.67% | 99.00% | 137.49% | 172.97% |
| Average Diluted Shares Outstanding | 35.73% | 60.67% | 99.00% | 137.49% | 172.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |